Ropes & Gray represented ImmunoGen, Inc., a leader in the field of antibody-drug conjugates, in an exclusive collaboration with Takeda Pharmaceutical Company Limited to develop and commercialize Immunogen’s ADC therapy ELAHERE in Japan. The collaboration was announced on August 28.
Under the collaboration and license agreement, ImmunoGen will receive an upfront payment and an additional payment upon conversion of FDA accelerated approval of ELAHERE in platinum-resistant ovarian cancer to full approval. ImmunoGen is eligible to receive additional payments if Takeda achieves certain regulatory and commercial milestones, as well as double-digit royalties on future net sales of ELAHERE in Japan. Immunogen has retained exclusive production rights and will supply product for development and commercial use in Japan. In exchange, Takeda will receive an exclusive license to develop and commercialize ELAHERE in Japan and is responsible for all regulatory filings.
The Ropes & Gray team was led by life sciences licensing partner Abigail Gregor, and included tax partner David Saltzman, tax counsel Michael Mendel and life sciences licensing associate Nicole Rohr.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find our more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.